Finasteride for Hair Loss: Clinical Evidence, Timeline, and Safety

Finasteride lowers DHT, the hormone that drives male pattern hair loss. It does this by blocking the type II form of 5-alpha reductase, the enzyme that converts testosterone into DHT. At the 1 mg daily dose used for hair loss, it cuts DHT by about 60% in the scalp and about 70% in the blood (Drake 1999).

DHT shortens the growth phase of scalp hair follicles in men who are genetically sensitive to it, so each cycle produces a finer, shorter hair until the follicle stops producing visible hair. Lowering DHT slows or halts that miniaturization, which is why finasteride protects the hair a man still has more reliably than it regrows hair already lost. It does not affect testosterone itself, which stays in the normal range.

The FDA approved finasteride 1 mg as Propecia for male pattern hair loss on December 19, 1997. The same molecule was approved earlier, in 1992, at a 5 mg dose (Proscar) for benign prostatic hyperplasia. Generic 1 mg finasteride became available in the United States after the hair-loss patent expired in November 2013, and it is now an inexpensive generic.

The hair-loss approval covers men only. Finasteride is not approved for women, and it carries a specific warning for women who are or may become pregnant, because blocking DHT can interfere with the development of a male fetus. Use in women is uncommon, off-label, and limited to specific situations a clinician manages directly.

The case for finasteride rests on a two-year randomized trial of 1,553 men aged 18 to 41 with mild to moderate hair loss (Kaufman 1998). After two years, 83% of men on finasteride had no further loss, measured by hair count, compared with continued loss in most men on placebo. Two-thirds, 66%, showed a measurable increase in hair count, and independent reviewers scoring photographs rated more finasteride-treated men as improved.

A later systematic review pooled the controlled trials and reached the same conclusion: finasteride 1 mg increases hair count and patient-rated and investigator-rated appearance versus placebo over one to two years (Mella 2010). The benefit is consistent across trials, though the size of the regrowth is modest and varies between men.

The evidence is strongest for the crown and weaker for the frontal hairline and temples, where follicles are often further along in miniaturization and less responsive to any drug.

Finasteride works slowly, and the first visible change is usually a halt in shedding rather than new growth. Most men need 3 to 6 months of daily use before they notice a difference, and about 12 months to judge the full effect, which is why the trials measured outcomes at one and two years rather than at a few weeks.

Some men see increased shedding in the first few weeks. This is generally short-lived and reflects follicles cycling into a new growth phase, not a sign the drug is failing.

The benefit depends on continued use. Hair count returns toward where it would have been within 6 to 12 months of stopping, because the drug controls the hormonal driver but does not cure the underlying sensitivity. There is no point at which a man can stop and keep the gains.

Most men tolerate finasteride without side effects, and the side effects that draw attention are sexual. In the two-year registration trial, the combined rate of sexual side effects, which covers lower libido, erectile difficulty, and reduced ejaculate volume, was 3.8% on finasteride versus 2.1% on placebo (Kaufman 1998). The difference between drug and placebo is real but small, on the order of 1 to 2 men in 100. In the trial these effects resolved in men who kept taking the drug and in all men who stopped.

A separate question is whether symptoms can persist after stopping. The FDA updated the Propecia label in 2012 to include post-marketing reports of sexual dysfunction that continued after discontinuation, along with reports of depressed mood. These come from spontaneous reports rather than controlled trials, so they show that the reports exist, not how often the outcome occurs or whether the drug caused it. A systematic review of the safety data concluded that the evidence on persistent effects is low quality and that a causal link is not established (Hirshburg 2016). The honest summary is that persistent symptoms are reported, appear to be uncommon, and remain debated.

Finasteride lowers PSA, a blood marker used in prostate cancer screening, by roughly half. This matters mainly for older men: anyone who has PSA testing should tell the clinician ordering it that they take finasteride, so the result can be interpreted correctly.

Dutasteride blocks both the type I and type II forms of 5-alpha reductase, while finasteride blocks mainly type II. As a result dutasteride lowers DHT more, and in a head-to-head randomized trial dutasteride 0.5 mg produced a greater increase in hair count than finasteride 1 mg over 24 weeks (Gubelin Harcha 2014). Dutasteride is approved for hair loss in some countries but not in the United States, where its use for hair loss is off-label.

Minoxidil works by a different route. It does not touch DHT; it appears to prolong the growth phase of the follicle and improve blood flow to the scalp. Because the mechanisms differ, finasteride and minoxidil are often used together, and the combination tends to outperform either drug alone. Topical minoxidil is available over the counter, while finasteride requires a prescription.

For most men starting treatment, finasteride 1 mg is the first-line oral option because it has the largest body of controlled evidence and an FDA approval for the use. Dutasteride is generally considered when finasteride is not enough.